The 2021 World Health Organization Central Nervous System Tumor Classification: The Spectrum of Diffuse Gliomas
Open Access
- 18 June 2024
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 12 (6) , 1349
Abstract
The 2021 edition of the World Health Organization (WHO) classification of central nervous system tumors introduces significant revisions across various tumor types. These updates, encompassing changes in diagnostic techniques, genomic integration, terminology, and grading, are crucial for radiologists, who play a critical role in interpreting brain tumor imaging. Such changes impact the diagnosis and management of nearly all central nervous system tumor categories, including the reclassification, addition, and removal of specific tumor entities. Given their pivotal role in patient care, radiologists must remain conversant with these revisions to effectively contribute to multidisciplinary tumor boards and collaborate with peers in neuro-oncology, neurosurgery, radiation oncology, and neuropathology. This knowledge is essential not only for accurate diagnosis and staging, but also for understanding the molecular and genetic underpinnings of tumors, which can influence treatment decisions and prognostication. This review, therefore, focuses on the most pertinent updates concerning the classification of adult diffuse gliomas, highlighting the aspects most relevant to radiological practice. Emphasis is placed on the implications of new genetic information on tumor behavior and imaging findings, providing necessary tools to stay abreast of advancements in the field. This comprehensive overview aims to enhance the radiologist’s ability to integrate new WHO classification criteria into everyday practice, ultimately improving patient outcomes through informed and precise imaging assessments.Keywords
This publication has 130 references indexed in Scilit:
- World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type GliomasJAMA Oncology, 2022
- Inactivation of RB1, CDKN2A, and TP53 have distinct effects on genomic stability at side‐by‐side comparison in karyotypically normal cellsGenes, Chromosomes and Cancer, 2022
- Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous systemCancer, 2021
- The International Collaboration for Cancer Classification and ResearchInternational Journal of Cancer, 2020
- Pediatric thalamic tumors in the MRI era: a Canadian perspectiveChild's Nervous System, 2015
- Oligodendroglioma: pathology, molecular mechanisms and markersActa Neuropathologica, 2015
- Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markersActa Neuropathologica, 2015
- Magnetic Resonance Imaging and Computed Tomography Findings in Pediatric Giant Cell GlioblastomaClinical Neuroradiology, 2012
- Monoclonal antibody specific for IDH1 R132H mutationActa Neuropathologica, 2009
- Analysis of the IDH1 codon 132 mutation in brain tumorsActa Neuropathologica, 2008